Therapeutic Benefit of Baseline PSA

Therapeutic Benefit of Baseline PSA: Lower Baseline PSA is Associated with a Greater Overall Survival Benefit from Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial

Dr. Leonard Gomella discusses an important topic that has been further defined based on the registration trial for sipuleucel-T, namely the therapeutic benefit that is seen in patients based on baseline PSA.

Click HERE to read an exclusive report by a UroToday medical writer

Leonard G. Gomella, MD, FACS - BIO

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.